Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moderna Inc MRNA

Healthcare Biotechnology
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular... see more

Recent & Breaking News (NDAQ:MRNA)

Moderna Announces Key 2020 Investor and Analyst Events

Business Wire December 11, 2019

François Nader, M.D., Joins Moderna's Board of Directors

Business Wire December 10, 2019

Moderna to Present at 31st Annual Piper Jaffray Healthcare Conference

Business Wire November 26, 2019

Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results

Business Wire November 6, 2019

Moderna to Present at Credit Suisse 28th Annual Healthcare Conference

Business Wire November 5, 2019

Moderna Named Top Employer by Science for Fifth Consecutive Year

Business Wire October 24, 2019

Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)

Business Wire October 22, 2019

Moderna to Report Third Quarter 2019 Financial Results on Wednesday, November 6th, 2019

Business Wire October 22, 2019

Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019

Business Wire October 2, 2019

Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927)

Business Wire September 30, 2019

Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University

Business Wire September 26, 2019

Moderna to Present at Upcoming Investor Conferences

Business Wire September 25, 2019

Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)

Business Wire September 12, 2019

Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials

Business Wire September 12, 2019

Moderna Appoints Tracey Franklin as Chief Human Resources Officer

Business Wire September 4, 2019

Moderna to Host R&D Day on September 12, 2019

Business Wire August 29, 2019

Moderna to Present at Upcoming Investor Conferences

Business Wire August 27, 2019

Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893

Business Wire August 19, 2019

Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results

Business Wire August 7, 2019

Moderna to Report Second Quarter 2019 Financial Results on Wednesday, August 7th, 2019

Business Wire July 24, 2019